B. infantis-based formulation PBCLN-014

{
  "id": "MLC-T-ONC-011856",
  "term": "B. infantis-based formulation PBCLN-014",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable formulation containing the naturally occurring lactic acid-producing gut bacteria Bifidobacterium longum subspecies infantis (B. infantis), with potential immunomodulating activity. Upon oral administration, B. infantis-based formulation PBCLN-014 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the gastrointestinal (GI) tract and may re-establish a healthy microbiome in the GI tract. This may improve intestinal barrier function, suppress inflammation, enhance the patients' immunological activity and lower the risk of GI antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease (GvHD) in patients undergoing solid organ and allogeneic stem cell transplantation.",
  "synonyms": [
    "Bifidobacterium longum subspecies infantis-based formulation PBCLN-014"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/b-infantis-based-formulation-pbcln-014/"
}